Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 84 articles: HTML format

Single Articles

October 2025
1. DHRUBA SR, Sahni S, Wang B, Wu D, et al
   Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.
   Cancer Lett. 2025 Oct 30:218101. doi: 10.1016/j.canlet.2025.218101.
   PubMed     Abstract available
   
   
   
2. YANG X, Xia Z
   Commentary: Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.
   Cancer Lett. 2025 Oct 30:218108. doi: 10.1016/j.canlet.2025.218108.
   PubMed    
   
   
   
3. KRAWCZYNSKA N, Wang Y, Lim K, Das Gupta A, et al
   Neutrophils exposed to a cholesterol metabolite secrete extracellular vesicles that promote epithelial-mesenchymal transition and stemness in breast cancer cells.
   Cancer Lett. 2025 Oct 28:218105. doi: 10.1016/j.canlet.2025.218105.
   PubMed     Abstract available
   
   
   
4. YAZDI N, Pourjamal N, Katainen R, Vaananen J, et al
   Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates.
   Cancer Lett. 2025;630:217900.
   PubMed     Abstract available
   
   
   September 2025
5. TAN C, Lyu H, Ruan S, Wu Y, et al
   Subtype-specific HER3 enrichment in basal-like breast cancer is regulated via the GATA2/GATA3-FOXA1 axis.
   Cancer Lett. 2025 Sep 2:218001. doi: 10.1016/j.canlet.2025.218001.
   PubMed     Abstract available
   
   
   
6. LIU K, Hoover AR, Sun Y, Valerio TI, et al
   Anti-tumor effects on tumor-infiltrating natural killer cells by localized ablative immunotherapy and immune checkpoint inhibitors: An integrated and comparative study using scRNAseq analysis.
   Cancer Lett. 2025;627:217825.
   PubMed     Abstract available
   
   
   August 2025
7. LI C, Gao T, Zhao Q, Li Z, et al
   Inhibition of CPT1A activates the cGAS/STING pathway to enhance neutrophil-mediated tumor abrogation in triple-negative breast cancer.
   Cancer Lett. 2025;633:217991.
   PubMed     Abstract available
   
   
   July 2025
8. RUPP B, Nagpal N, Thanasiu B, Tuck K, et al
   Multiplex characterization of circulating tumor cells from ductal carcinoma in situ patients suggests early tumor dissemination.
   Cancer Lett. 2025;623:217703.
   PubMed     Abstract available
   
   
   
9. CAI MY, Yin P, Wang ZW, Huang YZ, et al
   Dual Regulation of FZD1/7 by IGF2BP3 Enhances Stem-like Properties and Carboplatin Resistance in Triple-Negative Breast Cancer.
   Cancer Lett. 2025 Jul 22:217944. doi: 10.1016/j.canlet.2025.217944.
   PubMed     Abstract available
   
   
   
10. ZHANG M, Tang C, Li S, Jiang X, et al
    NSUN2-mediated m(5)C modification of KDM6B mRNA enhances osteoclast differentiation and promotes breast cancer bone metastasis.
    Cancer Lett. 2025 Jul 19:217939. doi: 10.1016/j.canlet.2025.217939.
    PubMed     Abstract available
    
    
    
11. WANG SC, Shen YC, Pan MR, Ou-Yang F, et al
    Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in Taiwan.
    Cancer Lett. 2025 Jul 10:217912. doi: 10.1016/j.canlet.2025.217912.
    PubMed     Abstract available
    
    
    
12. DI RUSSO S, Borsatti GE, Bouzidi A, Liberati FR, et al
    NF-kappaB-mediated cytokine secretion and glutamate metabolic reprogramming converge in breast cancer brain tropism.
    Cancer Lett. 2025 Jul 8:217907. doi: 10.1016/j.canlet.2025.217907.
    PubMed     Abstract available
    
    
    
13. TAKAO S, Furumoto H, Furusawa A, Kano M, et al
    Preserved host immunity with intercellular adhesion molecule-1 (ICAM-1)-targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of triple-negative breast cancer and other malignancies.
    Cancer Lett. 2025 Jul 7:217906. doi: 10.1016/j.canlet.2025.217906.
    PubMed     Abstract available
    
    
    
14. CHICA-PARRADO MR, Kim GM, Uemoto Y, Napolitano F, et al
    Corrigendum to "Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer" [604 (2024) 217219 1-12].
    Cancer Lett. 2025 Jul 5:217891. doi: 10.1016/j.canlet.2025.217891.
    PubMed    
    
    
    June 2025
15. HAYKAL MM, Rodrigues-Ferreira S, El Botty R, Sourd L, et al
    Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers.
    Cancer Lett. 2025;620:217665.
    PubMed     Abstract available
    
    
    
16. SABIT H, Adel A, Abdelfattah MM, Ramadan RM, et al
    The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities.
    Cancer Lett. 2025;628:217865.
    PubMed     Abstract available
    
    
    
17. ZHOU W, Ding Q
    Advancing Neoadjuvant Therapy with Inetetamab for HER2-Positive Breast Cancer.
    Cancer Lett. 2025 Jun 5:217852. doi: 10.1016/j.canlet.2025.217852.
    PubMed     Abstract available
    
    
    May 2025
18. WU R, Yu S, Bi A, Li Y, et al
    Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer.
    Cancer Lett. 2025 May 24:217823. doi: 10.1016/j.canlet.2025.217823.
    PubMed     Abstract available
    
    
    
19. ELAYAPILLAI SP, Dogra S, Hladik C, Lausen J, et al
    Preferential Release of microRNAs via Extracellular Vesicles is Associated with Ductal Carcinoma In Situ to Invasive Breast Cancer Progression.
    Cancer Lett. 2025 May 17:217794. doi: 10.1016/j.canlet.2025.217794.
    PubMed     Abstract available
    
    
    
20. UEMOTO Y, A Lin CC, Wang B, Ye D, et al
    Corrigendum to "Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations" [619 1 (2025) 217668 1-13].
    Cancer Lett. 2025;626:217782.
    PubMed    
    
    
    
21. WALTER V, Koch A, Hillmann D, Dannehl D, et al
    Association of CMV Status with Response to Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer.
    Cancer Lett. 2025 May 10:217789. doi: 10.1016/j.canlet.2025.217789.
    PubMed    
    
    
    
22. ZUO WJ, Ma LX, Wang ZH, Cao XC, et al
    Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial.
    Cancer Lett. 2025 May 10:217785. doi: 10.1016/j.canlet.2025.217785.
    PubMed     Abstract available
    
    
    
23. LIU S, Chen H, Gagea M, Federico L, et al
    ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.
    Cancer Lett. 2025 May 6:217775. doi: 10.1016/j.canlet.2025.217775.
    PubMed     Abstract available
    
    
    
24. JIANG C, Qian Y, Bai X, Li S, et al
    SLC7A5/E2F1/PTBP1/PKM2 axis mediates progression and therapy effect of triple-negative breast cancer through the crosstalk of amino acid metabolism and glycolysis pathway.
    Cancer Lett. 2025;617:217612.
    PubMed     Abstract available
    
    
    April 2025
25. GRIMSLEY HE, Antczak M, Reddin IG, Weiler N, et al
    Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkers.
    Cancer Lett. 2025 Apr 27:217754. doi: 10.1016/j.canlet.2025.217754.
    PubMed     Abstract available
    
    
    
26. XIE Y, Xie J, Huang G, Zhang J, et al
    Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple negative breast cancer.
    Cancer Lett. 2025 Apr 21:217734. doi: 10.1016/j.canlet.2025.217734.
    PubMed     Abstract available
    
    
    
27. KUNDU M, Greer YE, Lobanov A, Ridnour L, et al
    TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.
    Cancer Lett. 2025;620:217692.
    PubMed     Abstract available
    
    
    March 2025
28. LI H, Chatla S, Liu X, Tian Z, et al
    ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.
    Cancer Lett. 2025;613:217505.
    PubMed     Abstract available
    
    
    
29. UEMOTO Y, Lin CA, Wang B, Ye D, et al
    Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.
    Cancer Lett. 2025;619:217668.
    PubMed     Abstract available
    
    
    
30. YOU X, Hu X, Sun Z, Xu W, et al
    Dual targeting PPARalpha and NPC1L1 metabolic vulnerabilities blocks tumorigenesis.
    Cancer Lett. 2025;612:217493.
    PubMed     Abstract available
    
    
    
31. GILON-ZALTSMAN O, Weidenfeld-Barenboim K, Samara H, Feuermann Y, et al
    Targeting dormant disseminated tumor cells and their permissive niche by pro-resolving mediators derived from resolution-phase macrophages.
    Cancer Lett. 2025;612:217468.
    PubMed     Abstract available
    
    
    February 2025
32. ZENG Z, Yi Z, Xu B
    The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients.
    Cancer Lett. 2025 Feb 19:217574. doi: 10.1016/j.canlet.2025.217574.
    PubMed     Abstract available
    
    
    
33. CHEN H, Lin L, Qiao Z, Pei Y, et al
    YTHDF3 drives tumor growth and metastasis by recruiting eIF4B to promote Notch2 translation in breast cancer.
    Cancer Lett. 2025;614:217534.
    PubMed     Abstract available
    
    
    January 2025
34. ZHANG R, Jiang WJ, Zhao S, Kang LJ, et al
    FOXF2 expression triggered by endocrine therapy orchestrates therapeutic resistance through reorganization of chromatin architecture in breast cancer.
    Cancer Lett. 2025 Jan 17:217463. doi: 10.1016/j.canlet.2025.217463.
    PubMed     Abstract available
    
    
    
35. TAN N, Xia C, Yan X, Cao M, et al
    Extending breast cancer screening beyond age 45-64 years in China: a cost-effectiveness analysis.
    Cancer Lett. 2025 Jan 13:217457. doi: 10.1016/j.canlet.2025.217457.
    PubMed     Abstract available
    
    
    
36. USAMA M, Hsu YC, Safaei M, Chen CY, et al
    Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells.
    Cancer Lett. 2025;611:217453.
    PubMed     Abstract available
    
    
    
37. WANG Y, Zhou X, Lei Y, Chu Y, et al
    Corrigendum to "NNMT contributes to high metastasis of triple negative breast cancer by enhancing PP2A/MEK/ERK/c-Jun/ABCA1 pathway mediated membrane fluidity"[Cancer Lett. 547 (2022) 215884].
    Cancer Lett. 2025 Jan 3:217424. doi: 10.1016/j.canlet.2024.217424.
    PubMed    
    
    
    December 2024
38. JIA Y, Chen Y, Chen M, He M, et al
    Oncogenic HJURP enhancer promotes the aggressive behavior of triple-negative breast cancer in association with p53/E2F1/FOXM1-axis.
    Cancer Lett. 2024 Dec 28:217423. doi: 10.1016/j.canlet.2024.217423.
    PubMed     Abstract available
    
    
    
39. WANG K, He Q, Jiang X, Wang T, et al
    Targeting UBE2T suppresses breast cancer stemness through CBX6-mediated transcriptional repression of SOX2 and NANOG.
    Cancer Lett. 2024 Dec 21:217409. doi: 10.1016/j.canlet.2024.217409.
    PubMed     Abstract available
    
    
    November 2024
40. MUGHAL MJ, Zhang Y, Li Z, Zhou S, et al
    TFAP2C-DDR1 Axis Regulates Resistance to CDK4/6 Inhibitor in Breast Cancer.
    Cancer Lett. 2024 Nov 25:217356. doi: 10.1016/j.canlet.2024.217356.
    PubMed     Abstract available
    
    
    
41. GERRATANA L, Davis AA, Foffano L, Reduzzi C, et al
    Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling.
    Cancer Lett. 2024 Nov 20:217325. doi: 10.1016/j.canlet.2024.217325.
    PubMed     Abstract available
    
    
    
42. LIU K, Hoover AR, Wang L, Sun Y, et al
    Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells.
    Cancer Lett. 2024;604:217267.
    PubMed     Abstract available
    
    
    October 2024
43. BHATTARAI PY, Kim G, Lim SC, Choi HS, et al
    METTL3-STAT5B interaction facilitates the co-transcriptional m(6)A modification of mRNA to promote breast tumorigenesis.
    Cancer Lett. 2024;603:217215.
    PubMed     Abstract available
    
    
    September 2024
44. CHIANG CH, Xu XH, Song J, Xanthavanij N, et al
    The incidence and risk of cardiovascular events associated with pembrolizumab in patients with breast cancer.
    Cancer Lett. 2024 Sep 25:217277. doi: 10.1016/j.canlet.2024.217277.
    PubMed    
    
    
    
45. YU L, Wei W, Lv J, Lu Y, et al
    FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem cell activity.
    Cancer Lett. 2024 Sep 19:217271. doi: 10.1016/j.canlet.2024.217271.
    PubMed     Abstract available
    
    
    
46. WINNARD PT JR, Vesuna F, Bol GM, Gabrielson KL, et al
    Targeting RNA Helicase DDX3X with a Small Molecule Inhibitor for Breast Cancer Bone Metastasis Treatment.
    Cancer Lett. 2024 Sep 19:217260. doi: 10.1016/j.canlet.2024.217260.
    PubMed     Abstract available
    
    
    
47. LIU X, Ma Z, Jing X, Wang G, et al
    The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer.
    Cancer Lett. 2024 Sep 12:217232. doi: 10.1016/j.canlet.2024.217232.
    PubMed     Abstract available
    
    
    
48. CHICA-PARRADO MR, Kim GM, Uemoto Y, Napolitano F, et al
    Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.
    Cancer Lett. 2024 Sep 5:217219. doi: 10.1016/j.canlet.2024.217219.
    PubMed     Abstract available
    
    
    
49. ZHANG Z, Zhao M, Wang Q, Wang X, et al
    Forkhead box protein FOXK1 disrupts the circadian rhythm to promote breast tumorigenesis in response to insulin resistance.
    Cancer Lett. 2024;599:217147.
    PubMed     Abstract available
    
    
    August 2024
50. SRIVASTAVA P, Jha S, Singh SK, Vyas H, et al
    Protease activated receptor-1 regulates mixed lineage kinase-3 to drive triple-negative breast cancer tumorigenesis.
    Cancer Lett. 2024;603:217200.
    PubMed     Abstract available
    
    
    
51. MA Y, Zhang H, Shen X, Yang X, et al
    Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy.
    Cancer Lett. 2024;598:217102.
    PubMed     Abstract available
    
    
    
52. LIU B, Liu Y, Yang S, Ye J, et al
    Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes phenotypic plasticity and endocrine resistance in ER(+) breast cancer.
    Cancer Lett. 2024;600:217179.
    PubMed     Abstract available
    
    
    
53. GU T, Vasilatos SN, Yin J, Qin Y, et al
    Restoration of TFPI2 by LSD1 Inhibition Suppresses Tumor Progression and Potentiates Antitumor Immunity in Breast Cancer.
    Cancer Lett. 2024 Aug 16:217182. doi: 10.1016/j.canlet.2024.217182.
    PubMed     Abstract available
    
    
    
54. VIDANA GAMAGE HE, Albright ST, Smith AJ, Farmer R, et al
    Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells.
    Cancer Lett. 2024;597:217086.
    PubMed     Abstract available
    
    
    
55. VIDANA GAMAGE HE, Shahoei SH, Wang Y, Jacquin E, et al
    NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors.
    Cancer Lett. 2024;597:217042.
    PubMed     Abstract available
    
    
    
56. REGUA AT, Bindal S, Najjar MK, Zhuang C, et al
    Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Cancer Lett. 2024;597:217023.
    PubMed     Abstract available
    
    
    
57. YANG Y, Hao X, Zhang J, Gao T, et al
    The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling.
    Cancer Lett. 2024 Aug 8:217157. doi: 10.1016/j.canlet.2024.217157.
    PubMed     Abstract available
    
    
    July 2024
58. LI M, Zhang L, Guan T, Huang L, et al
    Energy stress-activated AMPK phosphorylates Snail1 and suppresses its stability and oncogenic function.
    Cancer Lett. 2024;595:216987.
    PubMed     Abstract available
    
    
    
59. LIU Y, Yin S, Lu G, Du Y, et al
    The intersection of the nervous system and breast cancer.
    Cancer Lett. 2024;598:217132.
    PubMed     Abstract available
    
    
    
60. ZHANG H, Zhang L, He Y, Jiang D, et al
    PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.
    Cancer Lett. 2024 Jul 8:217112. doi: 10.1016/j.canlet.2024.217112.
    PubMed     Abstract available
    
    
    
61. PERDRIX ROSELL A, Maiques O, Martin JAJ, Chakravarty P, et al
    Corrigendum to "Early functional mismatch between breast cancer cells and their tumour microenvironment suppresses long term growth" [Cancer Lett. 544 (2022), 215800].
    Cancer Lett. 2024 Jul 1:217078. doi: 10.1016/j.canlet.2024.217078.
    PubMed    
    
    
    June 2024
62. WAN YX, Qi XW, Lian YY, Liu ZY, et al
    Electroacupuncture Facilitates Vascular Normalization by Inhibiting Glyoxalase1 in Endothelial Cells to Attenuate Glycolysis and Angiogenesis in Triple-Negative Breast Cancer.
    Cancer Lett. 2024 Jun 28:217094. doi: 10.1016/j.canlet.2024.217094.
    PubMed     Abstract available
    
    
    
63. YU Y, Cao WM, Cheng F, Shi Z, et al
    FOXK2 amplification promotes breast cancer development and chemoresistance.
    Cancer Lett. 2024 Jun 18:217074. doi: 10.1016/j.canlet.2024.217074.
    PubMed     Abstract available
    
    
    
64. LIU J, Zhai M, Chen Y, Wei Y, et al
    Acetylation-dependent deubiquitinase USP26 stabilizes BAG3 to promote breast cancer progression.
    Cancer Lett. 2024 Jun 14:217005. doi: 10.1016/j.canlet.2024.217005.
    PubMed     Abstract available
    
    
    
65. WANG S, Xu L, Wang D, Zhao S, et al
    YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation.
    Cancer Lett. 2024 Jun 11:217047. doi: 10.1016/j.canlet.2024.217047.
    PubMed     Abstract available
    
    
    
66. LI SY, Zhang N, Zhang H, Wang N, et al
    Deciphering the TCF19/miR-199a-5p/SP1/LOXL2 pathway: Implications for breast cancer metastasis and epithelial-mesenchymal transition.
    Cancer Lett. 2024;597:216995.
    PubMed     Abstract available
    
    
    
67. ANDRIANI L, Ling YX, Yang SY, Zhao Q, et al
    Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting the TOLLIP-mediated autophagic degradation of CIP2A.
    Cancer Lett. 2024 Jun 5:217008. doi: 10.1016/j.canlet.2024.217008.
    PubMed     Abstract available
    
    
    
68. OLUWALANA D, Adeleye KL, Krutilina RI, Chen H, et al
    Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer.
    Cancer Lett. 2024 Jun 5:217011. doi: 10.1016/j.canlet.2024.217011.
    PubMed     Abstract available
    
    
    
69. RIVERA-RAMOS A, Cruz-Hernandez L, Talaveron R, Sanchez-Montero MT, et al
    Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth.
    Cancer Lett. 2024;591:216879.
    PubMed     Abstract available
    
    
    May 2024
70. SONG Y, Ren S, Chen X, Li X, et al
    Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics.
    Cancer Lett. 2024;590:216847.
    PubMed     Abstract available
    
    
    
71. LV Y, Sun S, Zhang J, Wang C, et al
    Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription.
    Cancer Lett. 2024 May 24:216988. doi: 10.1016/j.canlet.2024.216988.
    PubMed     Abstract available
    
    
    
72. LIN Z, Chen L, Wang Y, Zhang T, et al
    Improving Ultrasound Diagnostic Precision for Breast Cancer and Adenosis with Modality-Specific Enhancement (MSE) - Breast Net.
    Cancer Lett. 2024 May 23:216977. doi: 10.1016/j.canlet.2024.216977.
    PubMed     Abstract available
    
    
    
73. BELLI S, Esposito D, Ascione CM, Messina F, et al
    EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Cancer Lett. 2024 May 22:216968. doi: 10.1016/j.canlet.2024.216968.
    PubMed     Abstract available
    
    
    April 2024
74. ZHANG Y, Tan Y, Yuan J, Tang H, et al
    circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer.
    Cancer Lett. 2024;592:216907.
    PubMed     Abstract available
    
    
    
75. WANG J, Fan P, Shen P, Fan C, et al
    XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
    Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
    PubMed     Abstract available
    
    
    
76. LI K, Lin H, Liu A, Qiu C, et al
    SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
    Cancer Lett. 2024;590:216842.
    PubMed     Abstract available
    
    
    
77. ORHAN E, Velazquez C, Tabet I, Fenou L, et al
    CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Cancer Lett. 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820.
    PubMed     Abstract available
    
    
    
78. BULLOCK KK, Shattuck-Brandt R, Scalise C, Luo W, et al
    Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
    Cancer Lett. 2024;586:216681.
    PubMed     Abstract available
    
    
    March 2024
79. YANG Z, Chen H, Yin S, Mo H, et al
    PGR-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells.
    Cancer Lett. 2024 Mar 29:216795. doi: 10.1016/j.canlet.2024.216795.
    PubMed     Abstract available
    
    
    
80. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
    Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
    Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
    PubMed     Abstract available
    
    
    
81. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    PubMed     Abstract available
    
    
    February 2024
82. WANG X, Deng X, Hu J, Zheng W, et al
    K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 29:216764. doi: 10.1016/j.canlet.2024.216764.
    PubMed     Abstract available
    
    
    
83. SUN J, Du R, Li X, Liu C, et al
    CD63(+) cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20.
    Cancer Lett. 2024 Feb 23:216747. doi: 10.1016/j.canlet.2024.216747.
    PubMed     Abstract available
    
    
    
84. HAN BY, Chen C, Luo H, Lin CJ, et al
    Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.
    Cancer Lett. 2024 Feb 23:216763. doi: 10.1016/j.canlet.2024.216763.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.